Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immunology: Rheumatoid Arthritis (Mar 2017)

Posted by Matt Breese on Mar 27, 2017

Find me on:

According to our recent payer coverage analysis for rheumatoid arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this immunology drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access snapshot for RA treatments shows the dominance of the prior authorizations and step therapies. While these restrictions lifted slightly over the past quarter, the overall percentage of restricted lives across medicare and health exchange formularies increased. 


Source: MMIT data as of Q1 2017

Trends:  Recent news related to rheumatoid arthritis shows some key trends for prescribers and patients. One study, related to RA patients also suffering from depression, reveals that rheumatogists are working on better programs to help improve depression-related referrals and cooperation with their peers. Another study revealed how patient personality impacts product adherence for more aggressive treatment plans.

In the full Reality Check on rheumatoid arthritis treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on RA treatments with key findings on clinical characteristics, RA drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Branding & Marketing